UNICEF and other international bodies must produce a clear plan that prioritizes development and education for children with disabilities, especially in low- and middle-income settings, as required for achieving the United Nations Sustainable Development Goals.
). It is not too late for action. UNICEF, as the leading global advocate for child health and wellbeing, as well as the joint custodian of SDG 4.2, can reverse this trajectory for children with disabilities before 2030 by acting promptly and decisively on the recommendations in this article .
In January 2022, UNICEF launched the Strategic Plan 2022–2025, aimed at achieving the SDGs within its purview by 2030 . The organization rightfully pledged to prioritize the most marginalized children and adolescents, including children with disabilities, children affected by humanitarian crises, children on the move and children from the poorest households.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Nature's Nano-Syringes: Harnessing Bacterial Machines for Next-Gen MedicineBacterial Injection System Delivers Proteins in Mice and Human Cells With further development, the programmable system could be used in a range of applications including gene therapy and cancer therapy. Researchers at the Broad Institute of MIT and Harvard and the McGovern Institute for Brain Re
Read more »
Big tech companies invest billions in health research - Nature MedicineThey use proprietary data to understand human disease, while funding data science and brain research to support their AI ambitions
Read more »
It’s different for each person, but sometimes the best medicine is an extra pushIt’s different for each person, but sometimes the best medicine is an extra push to get outside, writes Alaska outdoors columnist Alli Harvey.
Read more »
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial - Nature MedicineIn a randomized phase 2 trial, sotigalimab, a CD40 agonist, did not significantly improve overall survival in patients with previously untreated metastatic pancreatic cancer when combined with chemotherapy or with nivolumab and chemotherapy. Multi-omic exploratory analyses provide insights into immunologic features associated with clinical benefit.
Read more »
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial - Nature MedicineIn a phase 2 trial, the combination of chemotherapy with durvalumab, an anti-PD-L1 antibody, exhibited promising clinical activity in patients with previously untreated, unresectable mesothelioma, with additional analyses providing insights into genomic and immunologic features potentially associated with response.
Read more »
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i - Nature MedicineAnalyses from the COMBI-i trial evaluating PD-1, BRAF and MEK inhibition in patients with metastatic melanoma demonstrate high response rates and uncover molecular correlates of long-term treatment benefit. Trial led by AACR23 speaker Reinhard Dummer
Read more »